Dyadic International, Inc.

NASDAQ:DYAI

Biotechnology

Healthcare
$1.47 +21.49%

+$0.26 today

Market cap
$53.56M
Beta
1.15
P/E (TTM)
-6.9
EPS (TTM)
-$0.20
52W Low $0.65High $1.55

Volume 0.71M

Average 0.31M

DYAI Long-term Debt

Borrowings due after more than one year.

Dyadic International, Inc.NASDAQ: DYAI

Long-term Debt · Q1 FY2026 · quarter ended Mar 2026

Long-term debt broadly unchanged from a year ago

Long-term debt stood at $5.03M at the end of Q1 FY2026, up 0.9% from a year earlier and up 0.1% from the prior quarter.

Context

  • Long-term debt amounted to 64.5% of total assets at the end of Q1 FY2026, up 1.3 pp from a year earlier.
  • Long-term debt increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether long-term debt keeps rising in the next quarterly balance sheet after a +0.9% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$5.03M+0.1% QoQ
Last fiscal yearDec 2025
$5.03M+1.0% YoY
Year agoMar 2025
$4.99M+0.9% since
Long-term Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+0.9%——
1 year+1.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Long-term Debt history

USD · from the balance sheet

Latest · FY2025
5.03M USD
Year-over-year change
+1.0%

Long-term Debt vs competitors

How DYAI compares with its peers on the latest reported figures

  • Peers report in different currencies, so long-term debt is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of +0.9% is the highest of 3, against a peer median of -100.0%.
  • Long-term debt amounts to 64.5% of total assets for DYAI, versus a peer median of 0.0%.
DYAI Competitors
Long-term Debt for DYAI and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
DYAIDyadic International, Inc.Mar 2026$5.03M USD+0.9%—64.5%
RNXTRenovoRx, Inc.Mar 2026$78K USD——0.6%
ATHEAlterity Therapeutics LimitedDec 2025A$0 AUD——0.0%
MAIAMAIA Biotechnology, Inc.Mar 2026$0 USD——0.0%
PYPDPolyPid Ltd.Mar 2026$0 USD-100.0%—0.0%
VERUVeru Inc.Mar 2026$0 USD——0.0%
ANVSAnnovis Bio, Inc.Mar 2026$0 USD——0.0%
CELUCelularity Inc.Dec 2025$0 USD-100.0%—0.0%
Peer median (excluding DYAI) —-100.0%—0.0%

Competitors are the stored peer set for DYAI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents15.75M5.79M6.52M6.51M4.62M
Short-term Investments4.51M6.85M748.29K2.76M2.7M
Net Receivables372.21K330K466.16K237.03K1.13M
Inventory00000
Other Current Assets058.29K10.08K24.25K1.23M
Total Current Assets21.01M13.42M8.07M9.83M9.9M
Property, Plant & Equipment (Net)00141.44K92.21K38.54K
Goodwill00000
Intangible Assets00000
Long-term Investments284.71K284.71K000
Tax Assets00000
Other Non-current Assets6.12K6.05K10.46K10.4K10.54K
Total Non-current Assets290.83K290.75K151.9K102.61K49.07K
Total Assets21.3M13.71M8.22M9.93M9.95M
Account Payables1.55M1.28M656.45K482.32K852.02K
Short-term Debt00000
Tax Payables00000
Deferred Revenue147.06K0000
Other Current Liabilities151.15K217.21K490.11K833.81K2.13M
Total Current Liabilities2.56M2.45M2.25M2.45M3.69M
Long-term Debt0004.98M5.03M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)352.94K0000
Other Non-current Liabilities0176.47K000
Total Non-current Liabilities352.94K176.47K88.87K5.01M5.03M
Total Liabilities2.91M2.63M2.34M7.46M8.71M
Common Stock40.48K40.82K41.07K42.09K48.44K
Retained Earnings(63.75M)(73.48M)(80.28M)(86.09M)(93.45M)
Accumulated OCI0(0)(0)(0)(0)
Other Stockholders Equity(0)0000
Minority Interest00000
Total Equity18.39M11.09M5.88M2.47M1.23M
Total Debt00136.93K5.07M5.06M
Net Debt(15.75M)(5.79M)(6.38M)(1.44M)438.33K

Dyadic International, Inc.

NASDAQ:DYAI

Intrinsic Alpha fair value

Locked

Current Price

$1.47

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.